mRNA Vaccines for Influenza

This trial tests new mRNA vaccines designed to protect against various strains of the influenza A virus. Researchers aim to determine if these vaccines are safe and elicit a strong immune response. Participants will receive one or two injections, depending on their study group. The trial seeks healthy adults who have maintained good health for at least the past two months and have not experienced major health issues recently. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

The trial does not specifically require you to stop taking your current medications. However, if you are on medications that affect the immune system or have had recent changes in your prescription, it might affect your eligibility. It's best to discuss your specific medications with the trial team to ensure they don't pose any additional risks.

Studies have shown that the mRNA vaccines being tested for the flu are safe. Previous research on similar vaccines indicates they are well-tolerated by people. Recipients of these vaccines experienced mild side effects, such as temporary soreness at the injection site or a mild fever. No serious side effects were reported in these studies.

For example, trials of the cH8/1N1 mRNA vaccine revealed no major safety concerns. The cH5/1N1 vaccine also demonstrated a good safety record in trials. Similarly, the cH15/3 and cH4/3 vaccines did not cause any serious problems.

Researchers are excited about these mRNA vaccines for influenza because they use cutting-edge mRNA technology to stimulate an immune response. Unlike traditional flu vaccines, which often use inactivated or weakened virus particles, these vaccines use snippets of genetic material to teach the body to recognize and attack the influenza virus. This approach allows for faster development and potentially broader protection against various flu strains. Moreover, mRNA vaccines can be quickly adapted to tackle emerging flu variants, offering a significant advantage over current seasonal flu vaccines.

Research has shown that mRNA vaccines for the flu, like those in this trial, hold promise. Participants will receive different combinations of these vaccines. For instance, the cH8/1N1 vaccine triggered strong immune responses in mice, protecting them against various flu strains. Similarly, the cH5/1N1 vaccine enhanced specific immune responses in humans, targeting key parts of the flu virus. The cH15/3 and cH4/3 vaccines are designed to offer broad protection against various flu types by stimulating specific antibodies. Overall, these mRNA vaccines aim to provide a wider and more effective defense against flu viruses compared to traditional vaccines.²⁴⁶⁷⁸